Rhythm Pharmaceuticals is likely to exceed US$750 million in rare-obesity drug sales in 2027, more than double the annual sales pace implied by its third-quarter 2026 results.

On 3 November LG Chem disclosed a revised licence for its experimental oral obesity drug, with Rhythm agreeing to an extra US$350 million in fixed payments in exchange for lower future royalties across its obesity-drug portfolio. The accompanying US$500 million committed loan facility should help cover those payments and clinical trials while protecting spending on finding patients and securing insurance cover. Rhythm can expand sales of its existing medicine Imcivree without waiting for the oral drug to win approval. Imcivree launched in Japan in October and European launches are planned from 2027. The number of patients on paid treatment worldwide rose 20% in the third quarter, while US doctors had submitted more than 700 treatment requests by September’s end. Japan’s initial prescription limits and European reimbursement negotiations could slow progress, so growth will depend on getting eligible patients onto regular paid treatment.